leukaemia
Janssen’s Imbruvica shows superiority in Phase 3 trials
June 4, 2019Manufacturing and Production Janssen, imbruvia, leukaemia, pharma, phase 3, trial
Phase 3 data from ASCO 2019 has shown Janssen’s leukaemia drug Imbruvica (ibrutinib) had significant benefits over ofatumumab. In the …
FDA greenlights Roche and AbbVie’s Venclexta for chronic lymphocytic leukaemia
May 16, 2019Sales and Marketing AbbVie, Cancer, FDA, Roche, Venclexta, leukaemia, pharma
Venclexta (venetoclax), the oral B-cell lymphoma-2 (BCL-2) inhibitor co-developed by AbbVie and Roche, has been approved by the FDA in …
Researchers find Achilles’ heel protein in leukaemia
April 26, 2019Medical Communications AML, Edinburgh, Protein, YTHDF2, blood cancer, drug targets, leukaemia
An international team of researchers have identified an “Achilles’ heel” protein that could lead to the development of novel treatments …
FDA halts Xencor’s acute myeloid leukaemia trial following two patient deaths
February 21, 2019Research and Development Cancer, FDA, Xencor, leukaemia, pharma
Cancer biopharma firm Xencor has revealed it is to place a hold on its ongoing Phase 1 trial of XmAb14045, …
BMS scores expanded European approval for Sprycel in paediatric leukaemia
February 13, 2019Research and Development, Sales and Marketing BMS, Cancer, Europe, Sprycel, leukaemia, pharma
Bristol-Myers Squibb’s Sprycel (dasatinib) has secured an expanded indication in Europe, the company said, with the European Commission greenlighting the …
Imbruvica combo scores expanded FDA approval in most common adult form of leukaemia
January 29, 2019Manufacturing and Production, Sales and Marketing AbbVie, Cancer, Janssen, imbruvica, leukaemia, pharma
It’s big news for Janssen and AbbVie as it emerged that their jointly-developed Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) …
Amgen’s Blincyto secures expanded indication in Europe for acute lymphoblastic leukaemia
January 23, 2019Research and Development, Sales and Marketing Ammgen, Cancer, Europe, European Commission, blincyto, leukaemia, pharma
The European Commission has chosen to expand the authorised indication for Amgen’s Blincyto (blinatumomab) in the region, it has emerged, …
Abbvie’s chronic lymphocytic leukaemia drug Venclytxo scores greenlight from NICE
January 18, 2019Medical Communications, Sales and Marketing AbbVie, NHS, NICE, Venclyxto, leukaemia, pharma
A new recommendation from NICE means that thousands of patients in England and Wales will be able to receive Abbvie’s …
Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma
December 3, 2018Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma
Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …
AbbVie’s Venclyxto combo beats standard of care in chronic lymphocytic leukaemia
December 3, 2018Research and Development, Sales and Marketing ASH 2018, AbbVie, Cancer, Venclyxto, leukaemia, pharma
AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on …
Novartis unveils strong longer-term Kymriah data at ASH 2018
December 3, 2018Research and Development, Sales and Marketing ASH 2018, Cancer, Kymriah, Novartis, leukaemia, pharma
Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of …
Pfizer’s Daurismo becomes first of its kind to secure FDA approval in acute myeloid leukaemia
November 22, 2018Research and Development, Sales and Marketing AML, Daurismo, FDA, Pfizer, US, leukaemia
Pfizer has revealed that the FDA has chosen to approve its Daurismo (glasdegib) for the treatment of newly-diagnosed acute myeloid …
Kymriah to be made available in UK for paediatric leukaemia patients via Cancer Drugs Fund
November 15, 2018Sales and Marketing CAR-T, Cancer, Cancer Drugs Fund, Kymriah, NHS, NICE, leukaemia, pharma
NICE has announced its recommendation that Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) be made available in the treatment of relapsed …
Azacitidine and nivolumab combo proves successful in phase II trial
November 13, 2018Manufacturing and Production Cancer, leukaemia, opdivo, pharma, texas
A combination of chemotherapy drug azacitidine and nivolumab (Bristol-Myers Squibb’s Opdivo) has proven effective in treating patients with relapsed or …
Working Life: Philippe Bastide, Head of Biosimilars, Mundipharma
November 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Mundipharma, Philippe Bastide, biosimilars, leukaemia
“Don’t conform to what people want – take risks. The people who make a big difference are the ones who …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
